Nanomedicine-Based Neuroprotective Strategies in Patient Specific-iPSC and Personalized Medicine
暂无分享,去创建一个
Wei-Hsiu Liu | Chung-Lan Kao | C. Kao | Hsin-I. Ma | Hsin-I Ma | Ming-Teh Chen | Shih-Fan Jang | Wen-Shin Song | Kuan-Lin Chiang | Ming-Teh Chen | Wei-Hsiu Liu | Shih-Fan Jang | Wen-Shin Song | Kuan-Lin Chiang
[1] T. Robbins,et al. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. , 2004, Brain : a journal of neurology.
[2] George Q. Daley,et al. Reprogramming of human somatic cells to pluripotency with defined factors , 2008, Nature.
[3] J. Cryan,et al. Non-viral nanosystems for gene and small interfering RNA delivery to the central nervous system: formulating the solution. , 2013, Journal of pharmaceutical sciences.
[4] Y. Yoon,et al. Induction of pluripotency in bone marrow mononuclear cells via polyketal nanoparticle-mediated delivery of mature microRNAs. , 2013, Biomaterials.
[5] J. Thomson,et al. Embryonic stem cell lines derived from human blastocysts. , 1998, Science.
[6] F. Alexis. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)] , 2005 .
[7] Rainer H Müller,et al. Lipid nanoparticles for parenteral delivery of actives. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[8] Silvia Licoccia,et al. Cerium oxide nanoparticles protect cardiac progenitor cells from oxidative stress. , 2012, ACS nano.
[9] A. Giordano,et al. Neuroprotective effects of PrxI over‐expression in an in vitro human Alzheimer's disease model , 2013, Journal of cellular biochemistry.
[10] Kwideok Park,et al. Fabrication of covered porous PLGA microspheres using hydrogen peroxide for controlled drug delivery and regenerative medicine. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[11] Lisa Brannon-Peppas,et al. Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.
[12] C. Peschle,et al. Identification of the hemangioblast in postnatal life. , 2002 .
[13] H. Harashima,et al. The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. , 2013, Biological & pharmaceutical bulletin.
[14] T. Ichisaka,et al. Generation of germline-competent induced pluripotent stem cells , 2007, Nature.
[15] Krishanu Saha,et al. Technical challenges in using human induced pluripotent stem cells to model disease. , 2009, Cell stem cell.
[16] P. Maincent,et al. Nanoparticle strategies for the oral delivery of insulin , 2008, Expert opinion on drug delivery.
[17] B. Sarmento,et al. Lipid-based colloidal carriers for peptide and protein delivery – liposomes versus lipid nanoparticles , 2007, International journal of nanomedicine.
[18] Aniruddha Roy,et al. Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[19] Rudolf Jaenisch,et al. Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.
[20] T. Ichisaka,et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.
[21] A. Herrmann,et al. Drug delivery systems based on nucleic acid nanostructures. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[22] Yao Sun. Myocardial repair/remodelling following infarction: roles of local factors. , 2008, Cardiovascular research.
[23] H. Deng,et al. Pluripotent Stem Cells Induced from Mouse Somatic Cells by Small-Molecule Compounds , 2013, Science.
[24] Susan Lindquist,et al. Generation of Isogenic Pluripotent Stem Cells Differing Exclusively at Two Early Onset Parkinson Point Mutations , 2011, Cell.
[25] R. Kumar,et al. Reduction in the Initial-Burst Release by Surface Crosslinking of PLGA Microparticles Containing Hydrophilic or Hydrophobic Drugs , 2005, Drug development and industrial pharmacy.
[26] C. Venkataraman,et al. Size distribution and dye release properties of submicron liposome aerosols , 2013 .
[27] T. Dawson. Unraveling the role of defective genes in Parkinson's disease. , 2007, Parkinsonism & related disorders.
[28] P. Knoepfler,et al. Inducing iPSCs to escape the dish. , 2011, Cell stem cell.
[29] M. Kaufman,et al. Establishment in culture of pluripotential cells from mouse embryos , 1981, Nature.
[30] J. Penney,et al. Trinucleotide repeat length instability and age of onset in Huntington's disease , 1993, Nature Genetics.
[31] R. Müller,et al. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[32] Amit Kumar,et al. Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[33] Jiangnan Yu,et al. Non‐Viral Co‐Delivery of the Four Yamanaka Factors for Generation of Human Induced Pluripotent Stem Cells via Calcium Phosphate Nanocomposite Particles , 2013 .
[34] Li-Li Zuo,et al. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. , 2013, Gene.
[35] S. Chiou,et al. Nonviral cell labeling and differentiation agent for induced pluripotent stem cells based on mesoporous silica nanoparticles. , 2013, ACS nano.
[36] Gann Ting,et al. Tumor Burden Talks in Cancer Treatment with PEGylated Liposomal Drugs , 2013, PloS one.
[37] S. Goldman. Stem and progenitor cell–based therapy of the human central nervous system , 2005, Nature Biotechnology.
[38] Balaji Narasimhan,et al. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. , 2013, Journal of controlled release : official journal of the Controlled Release Society.
[39] Christopher G Thanos,et al. Targeted nanoparticle-based drug delivery and diagnosis , 2007, Journal of drug targeting.
[40] C. Brunstein. Umbilical cord blood transplantation for the treatment of hematologic malignancies. , 2011, Cancer control : journal of the Moffitt Cancer Center.
[41] G. Ming,et al. Glial influences on neural stem cell development: cellular niches for adult neurogenesis , 2005, Current Opinion in Neurobiology.
[42] A. Kakita,et al. Relationship Among &agr;-Synuclein Accumulation, Dopamine Synthesis, and Neurodegeneration in Parkinson Disease Substantia Nigra , 2006, Journal of neuropathology and experimental neurology.
[43] Yan Zhang,et al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. , 2012, Biomaterials.
[44] Hongjun Song,et al. Adult neural stem cells in the mammalian central nervous system , 2009, Cell Research.
[45] K. Sen,et al. Second generation liposomal cancer therapeutics: transition from laboratory to clinic. , 2013, International journal of pharmaceutics.
[46] George Q. Daley,et al. Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.
[47] Shulan Tian,et al. Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.
[48] Daniel T. Montoro,et al. Characterization of Human Huntington's Disease Cell Model from Induced Pluripotent Stem Cells , 2010, PLoS currents.
[49] A. Álvarez-Buylla,et al. For the Long Run Maintaining Germinal Niches in the Adult Brain , 2004, Neuron.
[50] B Ruozi,et al. PLA/PLGA nanoparticles for sustained release of docetaxel. , 2006, International journal of pharmaceutics.
[51] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[52] D. P. O'Neal,et al. Simulation of transport and extravasation of nanoparticles in tumors which exhibit enhanced permeability and retention effect , 2013, Comput. Methods Programs Biomed..
[53] V. Préat,et al. PLGA-based nanoparticles: an overview of biomedical applications. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[54] Qizhi Zhang,et al. Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. , 2014, Biomaterials.
[55] M. MacDonald,et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. , 2000, Human molecular genetics.
[56] P. Conti,et al. Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. , 2013, Biomaterials.
[57] Jeffrey T. Leek,et al. Personalized medicine: Keep a way open for tailored treatments , 2012, Nature.
[58] R. Jain,et al. Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.
[59] E. Katunina,et al. [Epidemiology of Parkinson's disease]. , 2013, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.
[60] Vinit Kumar,et al. Fluorescent carbon nanoparticles in medicine for cancer therapy. , 2013, ACS medicinal chemistry letters.
[61] G. Martin,et al. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[62] Jun Liu,et al. Curcumin Ameliorates the Neurodegenerative Pathology in A53T α-synuclein Cell Model of Parkinson’s Disease Through the Downregulation of mTOR/p70S6K Signaling and the Recovery of Macroautophagy , 2013, Journal of Neuroimmune Pharmacology.
[63] M. McLaren. Kinetics of rod outer segment phagocytosis by cultured retinal pigment epithelial cells. Relationship to cell morphology. , 1996, Investigative ophthalmology & visual science.
[64] Y. Sasai,et al. In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction , 2009, Journal of Cell Science.
[65] Hynek Wichterle,et al. Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons , 2008, Science.
[66] Kwangmeyung Kim,et al. Dextran sulfate-coated superparamagnetic iron oxide nanoparticles as a contrast agent for atherosclerosis imaging. , 2014, Carbohydrate polymers.
[67] Krishanu Saha,et al. Pluripotency and Cellular Reprogramming: Facts, Hypotheses, Unresolved Issues , 2010, Cell.
[68] C. Ross,et al. Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.
[69] A. Vortmeyer,et al. Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. , 2006, Cancer research.
[70] Jane S. Paulsen,et al. CAG‐repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[71] C. von Kalle,et al. Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable. , 2004, Seminars in hematology.
[72] G. P. Agrawal,et al. Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir , 2013, Drug development and industrial pharmacy.
[73] Li Xue,et al. The anti-melanoma efficiency of the intratumoral injection of cucurbitacin-loaded sustained-release carriers: a PLGA particle system. , 2013, Journal of pharmaceutical sciences.
[74] A. Giordano,et al. A Commentary on iPS Cells: Potential Applications in Autologous Transplantation, Study of Illnesses and Drug Screening , 2014, Journal of cellular physiology.
[75] D. Chirio,et al. Preparation of solid lipid nanoparticles from W/O/W emulsions: Preliminary studies on insulin encapsulation , 2009, Journal of microencapsulation.
[76] Huck-Hui Ng,et al. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. , 2009, Cell stem cell.
[77] C. Svendsen,et al. Induced pluripotent stem cells: a new revolution for clinical neurology? , 2011, The Lancet Neurology.
[78] Sudesh Kumar Yadav,et al. Biodegradable polymeric nanoparticles based drug delivery systems. , 2010, Colloids and surfaces. B, Biointerfaces.
[79] T. Shimazaki,et al. [Mammalian neural stem cells]. , 2008, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[80] G. Fishman,et al. iPS cell modeling of Best disease: insights into the pathophysiology of an inherited macular degeneration. , 2013, Human molecular genetics.
[81] Diane J. Burgess,et al. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[82] J. Trojanowski,et al. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.
[83] T. Gillis,et al. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. , 2012, Cell stem cell.
[84] M. Ang,et al. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye , 2012, International journal of nanomedicine.
[85] Kristopher L. Nazor,et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells , 2012, Nature.
[86] Ji Young Kim,et al. Robust Enhancement of Neural Differentiation from Human ES and iPS Cells Regardless of their Innate Difference in Differentiation Propensity , 2010, Stem Cell Reviews and Reports.
[87] H. Sugiyama,et al. A synthetic small molecule for rapid induction of multiple pluripotency genes in mouse embryonic fibroblasts , 2012, Scientific Reports.
[88] T. Mikkelsen,et al. Dissecting direct reprogramming through integrative genomic analysis , 2008, Nature.
[89] S. Finkbeiner,et al. Modeling Huntington's disease with induced pluripotent stem cells , 2013, Molecular and Cellular Neuroscience.
[90] C. Cho,et al. Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation. , 2005, Cancer biotherapy & radiopharmaceuticals.
[91] S. Prabhu,et al. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. , 2005, International journal of pharmaceutics.
[92] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[93] Shinya Yamanaka,et al. Immunogenicity of induced pluripotent stem cells. , 2011, Circulation research.
[94] James A. Thomson,et al. Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.
[95] Leaf Huang,et al. Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.
[96] Lie-Chwen Lin,et al. Optimised nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving rats. , 2011, Food chemistry.
[97] K. Hochedlinger,et al. Induced pluripotency: history, mechanisms, and applications. , 2010, Genes & development.
[98] Yoshimasa Tanaka,et al. Clinical grade iPS cells: need for versatile small molecules and optimal cell sources. , 2013, Chemistry & biology.
[99] S. Laurent,et al. Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging. , 2013, International journal of pharmaceutics.
[100] M. Adomako,et al. Oral DNA vaccination of rainbow trout, Oncorhynchus mykiss (Walbaum), against infectious haematopoietic necrosis virus using PLGA [Poly(D,L-Lactic-Co-Glycolic Acid)] nanoparticles. , 2012, Journal of fish diseases.
[101] A. Almeida,et al. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. , 2007, Advanced drug delivery reviews.
[102] R. Ferrante,et al. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. , 2009, Biochimica et biophysica acta.